PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2008; 10(5): 406.
Published online Sep 9, 2008. doi:  10.1186/ar2499
PMCID: PMC2592784
Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
Thomas Dörner,corresponding author1 Joerg Kaufmann,1 William A Wegener,2 Nick Teoh,2 David M Goldenberg,2,3 and Gerd R Burmester1
1Department of Medicine/Rheumatology and Clinical Immunology, Charite Hospital, Berlin, Germany
2Immunomedics, Inc., Morris Plains, NJ, USA
3Center for Molecular Medicine and Immunology, Belleville, NJ, USA
corresponding authorCorresponding author.
Thomas Dörner: thomas.doerner/at/charite.de
Following publication of our article [1] we noticed an error in the stated dose of methotrexate within the section 'Results', in the paragraph 'Demographics and patient characteristics at study entry'.
In this paragraph, it is stated that two patients were receiving 20 mg/day methotrexate. This should read 20 mg/week methotrexate.
The paragraph should therefore read as follows:
A total of 14 Caucasian patients (13 females and 1 male; 23 to 53 years old, median age 40 years) were enrolled. At study entry, the patients had been initially diagnosed with SLE 1 to 19 years (median 10 years) earlier and were receiving corticosteroids (n = 13, 1 to 12 mg/day prednisolone) plus immunosuppressives (n = 11, including 50 to 200 mg/day azathioprine, n = 9; 20 mg/week methotrexate, n = 2; 2 g/day mycophenalate mofetil, n = 1), and antimalarials (n = 6, 200 to 600 mg/day hydroxychloroquine). All patients had positive ANA at study entry (titers of 80:1 to 5,120:1), and 5 patients (36%) had positive anti-dsDNA antibody levels (> 10 U/ml). Ten patients (71%) had ESR values that were elevated (> 15 mm/h) and 4 patients (29%) had raised CRP levels (> 0.5 mg/dl), while only 3 patients (21%) had C3 levels that were borderline low or decreased (< 90 mg/dl), and no patient had positive direct Coombs' or serum haptoglobulin levels elevated above borderline.
Notes
See related research by Dörner et al., http://arthritis-research.com/content/8/3/R74
References
  • Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Research & Therapy. 2006;8:R74. doi: 10.1186/ar1942. [PMC free article] [PubMed] [Cross Ref]
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central